Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Market capitalization of Inhibrx, Inc. (INBX)
Market cap: $209.76 M
As of Dec 2024 Inhibrx, Inc. has a market cap of $209.76 M. This makes Inhibrx, Inc. the world's most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Inhibrx, Inc. from 2001 to 2023
Market Cap History
| Date | Market cap |
|---|---|
| 26 Dec 2024 | $231.09 M |
| 24 Dec 2024 | $224.13 M |
| 23 Dec 2024 | $223.82 M |
| 20 Dec 2024 | $225.83 M |
| 19 Dec 2024 | $214.7 M |
| 18 Dec 2024 | $217.94 M |
| 17 Dec 2024 | $225.06 M |
| 16 Dec 2024 | $225.21 M |
| 13 Dec 2024 | $226.14 M |
| 12 Dec 2024 | $228.15 M |
| 11 Dec 2024 | $233.88 M |
| 10 Dec 2024 | $231.56 M |
| 09 Dec 2024 | $230.94 M |
| 06 Dec 2024 | $242.85 M |
| 05 Dec 2024 | $233.57 M |
| 04 Dec 2024 | $233.57 M |
| 03 Dec 2024 | $232.02 M |
| 02 Dec 2024 | $233.26 M |
| 29 Nov 2024 | $236.04 M |
| 27 Nov 2024 | $241.76 M |
| 26 Nov 2024 | $238.98 M |
| 25 Nov 2024 | $229.85 M |
| 22 Nov 2024 | $217.79 M |
| 21 Nov 2024 | $216.24 M |
| 20 Nov 2024 | $217.17 M |
| 19 Nov 2024 | $221.04 M |
| 18 Nov 2024 | $210.67 M |
| 15 Nov 2024 | $213.92 M |
| 14 Nov 2024 | $221.66 M |
| 13 Nov 2024 | $238.98 M |
| 12 Nov 2024 | $256.46 M |
| 11 Nov 2024 | $247.49 M |
| 08 Nov 2024 | $234.65 M |
| 07 Nov 2024 | $235.38 M |
| 06 Nov 2024 | $232.34 M |
| 05 Nov 2024 | $227.42 M |
| 04 Nov 2024 | $225.1 M |
| 01 Nov 2024 | $228.72 M |
| 31 Oct 2024 | $232.05 M |
| 30 Oct 2024 | $235.81 M |
| 29 Oct 2024 | $233.06 M |
| 28 Oct 2024 | $231.61 M |
| 25 Oct 2024 | $222.49 M |
| 24 Oct 2024 | $222.49 M |
| 23 Oct 2024 | $228.14 M |
| 22 Oct 2024 | $228.72 M |
| 21 Oct 2024 | $224.38 M |
| 18 Oct 2024 | $231.61 M |
| 17 Oct 2024 | $234.08 M |
| 16 Oct 2024 | $232.34 M |
| 15 Oct 2024 | $227.85 M |
| 14 Oct 2024 | $224.38 M |
| 11 Oct 2024 | $226.4 M |
| 10 Oct 2024 | $225.53 M |
| 09 Oct 2024 | $226.84 M |
| 08 Oct 2024 | $231.47 M |
| 07 Oct 2024 | $221.05 M |
| 04 Oct 2024 | $213.66 M |
| 03 Oct 2024 | $215.4 M |
| 02 Oct 2024 | $222.93 M |
| 01 Oct 2024 | $223.65 M |
| 30 Sep 2024 | $226.69 M |
| 27 Sep 2024 | $224.67 M |
| 26 Sep 2024 | $221.92 M |
| 25 Sep 2024 | $223.22 M |
| 24 Sep 2024 | $224.38 M |
| 23 Sep 2024 | $226.84 M |
| 20 Sep 2024 | $235.67 M |
| 19 Sep 2024 | $253.18 M |
| 18 Sep 2024 | $245.95 M |
| 17 Sep 2024 | $249.28 M |
| 16 Sep 2024 | $252.32 M |
| 13 Sep 2024 | $237.55 M |
| 12 Sep 2024 | $218.3 M |
| 11 Sep 2024 | $217.14 M |
| 10 Sep 2024 | $219.74 M |
| 09 Sep 2024 | $220.03 M |
| 06 Sep 2024 | $218.01 M |
| 05 Sep 2024 | $232.19 M |
| 04 Sep 2024 | $232.19 M |
| 03 Sep 2024 | $230.89 M |
| 30 Aug 2024 | $210.77 M |
| 29 Aug 2024 | $201.36 M |
| 28 Aug 2024 | $202.08 M |
| 27 Aug 2024 | $205.41 M |
| 26 Aug 2024 | $201.65 M |
| 23 Aug 2024 | $193.11 M |
| 22 Aug 2024 | $188.04 M |
| 21 Aug 2024 | $188.91 M |
| 20 Aug 2024 | $186.88 M |
| 19 Aug 2024 | $187.46 M |
| 16 Aug 2024 | $180.37 M |
| 15 Aug 2024 | $179.5 M |
| 14 Aug 2024 | $163.43 M |
| 13 Aug 2024 | $163.58 M |
| 12 Aug 2024 | $162.85 M |
| 09 Aug 2024 | $159.81 M |
| 08 Aug 2024 | $165.6 M |
| 07 Aug 2024 | $165.89 M |
| 06 Aug 2024 | $171.83 M |
| 05 Aug 2024 | $180.08 M |
| 02 Aug 2024 | $205.99 M |
| 01 Aug 2024 | $210.91 M |
| 31 Jul 2024 | $210.05 M |
| 30 Jul 2024 | $206.72 M |
| 29 Jul 2024 | $207.01 M |
| 26 Jul 2024 | $198.75 M |
| 25 Jul 2024 | $194.41 M |
| 24 Jul 2024 | $194.7 M |
| 23 Jul 2024 | $206.28 M |
| 22 Jul 2024 | $195.28 M |
| 19 Jul 2024 | $186.45 M |
| 18 Jul 2024 | $187.9 M |
| 17 Jul 2024 | $201.36 M |
| 16 Jul 2024 | $208.6 M |
| 15 Jul 2024 | $200.64 M |
| 12 Jul 2024 | $192.38 M |
| 11 Jul 2024 | $191.81 M |
| 10 Jul 2024 | $187.75 M |
| 09 Jul 2024 | $188.48 M |
| 08 Jul 2024 | $197.02 M |
| 05 Jul 2024 | $186.59 M |
| 03 Jul 2024 | $194.56 M |
| 02 Jul 2024 | $196.29 M |
| 01 Jul 2024 | $198.9 M |
| 28 Jun 2024 | $205.12 M |
| 27 Jun 2024 | $203.53 M |
| 26 Jun 2024 | $211.64 M |
| 25 Jun 2024 | $218.44 M |
| 24 Jun 2024 | $223.94 M |
| 21 Jun 2024 | $219.17 M |
| 20 Jun 2024 | $209.76 M |
| 18 Jun 2024 | $210.91 M |
| 17 Jun 2024 | $205.41 M |
| 14 Jun 2024 | $227.27 M |
| 13 Jun 2024 | $240.16 M |
| 12 Jun 2024 | $239.14 M |
| 11 Jun 2024 | $243.77 M |
| 10 Jun 2024 | $240.16 M |
| 07 Jun 2024 | $241.02 M |
| 06 Jun 2024 | $235.09 M |
| 05 Jun 2024 | $244.5 M |
| 04 Jun 2024 | $249.13 M |
| 03 Jun 2024 | $260.86 M |
| 31 May 2024 | $235.23 M |
End of Day market cap according to different sources
Market capitalization for similar companies or competitors
| Name | Market cap | Country |
|---|---|---|
Crinetics Pharmaceuticals, Inc.
MSFT
|
$4.98 B |
 US
|
DICE Therapeutics, Inc.
MSFT
|
$2.27 B |
US
|
Design Therapeutics, Inc.
MSFT
|
$362.37 M |
US
|
Ikena Oncology, Inc.
MSFT
|
$75.77 M |
US
|
Kronos Bio, Inc.
MSFT
|
$54.61 M |
US
|
Larimar Therapeutics, Inc.
MSFT
|
$241.19 M |
US
|
Lyell Immunopharma, Inc.
MSFT
|
$200.45 M |
US
|
Merrimack Pharmaceuticals, Inc.
MSFT
|
$223.97 M |
US
|
Mineralys Therapeutics, Inc.
MSFT
|
$640.52 M |
US
|
Merus N.V.
MSFT
|
$2.9 B |
 NL
|
Opthea Limited
MSFT
|
$4.57 B |
 AU
|
Protagonist Therapeutics, Inc.
MSFT
|
$2.34 B |
US
|
Stoke Therapeutics, Inc.
MSFT
|
$599.59 M |
US
|
Viridian Therapeutics, Inc.
MSFT
|
$1.55 B |
US
|